A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Clinical trial NCT07581002 · RECRUITING
Trial details
- NCT number
- NCT07581002
- Sponsor
- AbbVie
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-30
- Primary completion
- 2032-05-01
- Enrollment
- 660
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.